WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.

WuXi Biologics (Cayman) Inc.

WuXi Biologics provides contract research, development, and manufacturing services for biologics, offering end-to-end solutions from discovery to commercialization.

msh id	COM:WUXIBIOLOGICS
symbol	2.27K
name	WuXi Biologics (Cayman) Inc.
homepage url	https://www.wuxibiologics.com
country	CN
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	12.74K
crunchbase url	-
linkedin url	-
founders	-

market cap	5.94B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.23
growth cost of revenue	0.19
growth depreciation and amortization	-0.1
growth ebitda	-0.33
growth ebitda ratio	-0.4
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.18
growth gross profit	0.02
growth gross profit ratio	-0.09

2269

COM:WUXIBIOLOGICS

WuXi Biologics

Last Close

15.00

22/11 02:45

Market Cap

46.18B

Beta: -

Volume Today

14.97M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	1.79B
cost of revenue	1.79B
depreciation and amortization	99.33M
ebitda	642.9M
ebitda ratio	0.27
eps	0.11
eps diluted	0.11
operating expenses	375.23M
operating income	543.57M
operating income ratio	0.23

accounts receivables	-
capital expenditure	-
cash at beginning of period	883.93M
cash at end of period	883.93M
inventory	244.06M
working capital ttm	9.74B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-